What is PreOmics?
Founded in 2016, PreOmics specializes in the development of sophisticated workflows designed to streamline protein analysis. The company serves as a critical partner for life science organizations, providing the tools necessary to translate complex biological data into actionable knowledge. By focusing on efficiency and reliability, PreOmics has carved out a distinct market position, effectively bridging the gap between raw sample preparation and high-throughput analytical output. Their technology is increasingly viewed as a standard-bearer for laboratories seeking to optimize their proteomic research capabilities.
How much funding has PreOmics raised?
PreOmics has raised a total of $17.9M across 2 funding rounds:
Series A
$2.7M
Series B
$15.2M
Series A (2018): $2.7M, investors not publicly disclosed
Series B (2022): $15.2M led by High-Tech Gründerfonds and Bruker
Key Investors in PreOmics
High-Tech Gründerfonds
High-Tech Gruenderfonds is a public-private venture capital investment company. It offers seed financing that provides ideas for start-ups in the prototyping phase. The company was founded in 2005 and is headquartered in Berlin, Germany.
Bruker
Bruker Corporation is a global leader in scientific instrumentation, analytical technologies, and diagnostic solutions, serving customers across research, industry, and government.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for PreOmics?
With the successful closure of this major enterprise-level funding, PreOmics is poised to enter a phase of aggressive operational scaling and market expansion. The strategic alignment with industry leaders suggests a focus on integrating their proprietary workflows into broader diagnostic and research ecosystems. Future growth will likely center on enhancing the scalability of their product portfolio, expanding their international footprint, and deepening their research and development efforts to maintain a competitive edge in the rapidly evolving field of proteomics. As the company transitions from a scaling entity to a market leader, the focus will remain on driving adoption across pharmaceutical, biotechnology, and clinical research sectors.
See full PreOmics company page
